Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 12/20 | 0.46 |
| ▸ | CA2 | P00918 | 12/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22574596 | 1.00 | MEN1 (0.64) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL4107078 | 0.95 | TDP1 (0.61) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL30915267 | 0.95 | TDP1 (0.61) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL4107080 | 0.95 | TDP1 (0.61) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL19007632 | 0.90 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL12954842 | 0.90 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL12668248 | 0.89 | MEN1 (0.62) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL6665327 | 0.87 | MEN1 (0.64) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL21190311 | 0.86 | MEN1 (0.62) | MEN1GAAKMT2ATDP1MAOA | |
| Hydrochloric Acid SCHEMBL6122869 | 0.86 | MEN1 (0.62) | MEN1GAAKMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111511740-B | Amide substituted imidazo [4,5-C ] quinoline compounds with branched linking groups for use as immune response modifiers | 3M创新有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11306083-B2 | Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3728255-B1 | AMIDE SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH A BRANCHED CHAIN LINKING GROUP FOR USE AS AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210101898-A1 | AMIDE SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH A BRANCHED CHAIN LINKING GROUP FOR USE AS AN IMMUNE RESPONSE MODIFIER | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2021-04-08 | — | — | US | disclosed |
| EP-3728255-A1 | AMIDE SUBSTITUED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH A BRANCHED CHAIN LINKING GROUP FOR USE AS AN IMMUNE RESPONSE MODIFIER | 3M Innovative Properties Company (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-1697400-B1 | BIPHENYL-SUBSTITUTED ANTIBACTERIAL MACROCYCLES | AICURIS GMBH & CO KG (DE) | 2011-05-25 | — | — | EP | disclosed |
| US-7655643-B2 | Antibacterial macrocycles with substituted biphenyl | AICURIS GMBH & CO. KG (DE) | 2010-02-02 | — | — | US | disclosed |
| US-20070099885-A1 | Antibacterial macrocycles with substituted biphenyl | AICURIS GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099885-A1 | Antibacterial macrocycles with substituted biphenyl | NOD2, AHR, BCL2 | MEN1 1957/4885GAA 810/4885KMT2A 3328/4885 |
| US-20210101898-A1 | AMIDE SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH A BRANCHED CHAIN LINKING GROUP FOR USE AS AN IMMUNE RESPONSE MODIFIER | IFNG, IFNAR1, IL2 | MEN1 2411/4885GAA 2198/4885KMT2A 2685/4885 |
| US-11306083-B2 | Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier | IFNG, IFNAR1, IL2 | MEN1 2411/4885GAA 2198/4885KMT2A 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.